Zymeworks Inc.

ZYME

Zymeworks Inc.

ZYME

Insider Sentiment (TTM):

Last Purchase:2025-05-19Last Sale:2026-01-12Shares Purchased (TTM):0Shares Sold (TTM):187,933

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:69,694,986Shares Outstanding:74,668,790Institutional Ownership Pct.:93.34%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	179	244	41	65	98	76	66	122	71	115	158	94
Debt Securities Available For Sale Excluding Accru…	91	120	188	187	183	189	160	175	259	230	217	-
Short Term Investments	-	-	-	-	-	-	-	-	-	-	217	201
Accounts Receivable Net Current	6	5	5	29	3	25	56	24	32	31	19	67
Prepaid Expense And Other Assets Current	22	16	15	10	12	17	19	23	21	18	19	12
Assets Current	298	386	249	292	296	306	300	344	383	394	413	375
Debt Securities Available For Sale Excluding Accru…	52	39	42	47	52	56	98	78	66	75	82	-
Prepaid Expense And Other Assets Noncurrent	2	7	7	7	9	9	9	7	7	8	8	-
Long Term Investments	-	-	-	-	-	-	-	-	-	-	82	96
Prepaid Expense Noncurrent	-	-	-	-	-	-	-	-	-	-	7	8
Deferred Income Tax Assets Net	4	5	5	5	5	5	4	4	4	4	4	1
Property Plant And Equipment Net	14	15	16	16	16	17	18	18	18	19	20	21
Operating Lease Right Of Use Asset	13	14	16	17	16	17	17	17	17	17	18	18
Finite Lived Intangible Assets Net	1	1	1	1	2	3	5	6	7	7	8	8
Indefinite Lived Intangible Assets Excluding Goodw…	-	-	-	-	-	-	0	-	0	18	18	18
Goodwill	12	12	12	12	12	12	12	12	12	12	12	12
Assets	397	478	347	397	408	426	463	487	516	554	581	556
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	27	30	36	34	31	38	60	52	44	47	46	68
Accrued Income Taxes Current	0	0	0	1	0	0	0	2	2	2	2	1
Operating Lease Liability Current	3	3	3	3	4	3	3	3	3	4	4	4
Contract With Customer Liability Current	16	2	2	3	4	23	26	27	6	3	4	0
Derivative Fair Value Of Derivative Liability	-	-	-	-	-	-	-	-	-	-	1	0
Liabilities Current	47	36	42	42	39	65	88	84	55	57	56	73
Operating Lease Liability Noncurrent	13	14	15	16	15	15	16	17	17	21	22	22
Contract With Customer Liability Noncurrent	0	15	15	15	15	15	15	15	33	33	33	33
Other Liabilities Noncurrent	0	0	0	0	1	1	1	1	1	2	2	2
Deferred Income Tax Liabilities Net	4	4	6	5	5	5	5	3	3	3	3	2
Liabilities	317	315	78	77	74	101	124	120	109	116	116	132
Stockholders Equity
Common Stock Value	1,134	1,129	1,105	1,093	1,074	1,022	1,016	1,014	1,005	1,003	997	932
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	116	108	115	111	109	154	152	148	147	143	142	154
Accumulated Other Comprehensive Income Loss Net Of…	-7	-7	-6	-6	-6	-6	-7	-6	-8	-8	-7	-8
Retained Earnings Accumulated Deficit	-1,171	-1,074	-953	-886	-851	-853	-830	-798	-747	-709	-677	-663
Stockholders Equity	80	164	269	320	335	325	339	367	406	438	465	424
Liabilities And Stockholders Equity	397	478	347	397	408	426	463	487	516	554	581	556
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	900	900	900	900	900	900	900	900	900	900	900	900
Common Stock Shares Issued	71	73	75	75	75	70	69	70	71	71	70	68
Shares Outstanding	71	73	75	75	75	70	69	70	71	71	70	68
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.53%	-9.21%	-14.06%	-	-	-	-	-	-	-	-	-
2025	0.97%	10.16%	17.76%	21.79%	36.51%	45.89%	49.22%	50.11%	29.83%	3.73%	20.55%	9.87%
2024	-3.11%	-6.56%	8.67%	12.66%	29.48%	33.33%	4.31%	3.21%	1.31%	-6.15%	-4.63%	-12.44%
2023	-	-	-	-3.48%	-18.30%	-14.30%	24.15%	40.98%	41.11%	-13.98%	-32.46%	-28.70%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.32	10.82	5.88	6.94	7.69	4.71	3.40	4.10	7.01	6.92	7.41	5.14
Quick Ratio	5.86	10.36	5.52	6.69	7.38	4.45	3.19	3.82	6.62	6.61	7.06	4.98
Working Capital	251.15M	350.03M	206.45M	249.67M	257.63M	241.36M	212.16M	259.86M	328.78M	336.93M	357.16M	301.79M
Leverage & Debt
Debt to Equity	3.94	1.92	0.29	0.24	0.22	0.31	0.37	0.33	0.27	0.26	0.25	0.31
Interest Coverage TTM	-12.44	-9.02	-6.93	-4.88	-5.26	-7.16	-6.88	-6.62	-6.49	-7.14	-7.01	3.87
Debt Ratio	0.80	0.66	0.23	0.19	0.18	0.24	0.27	0.25	0.21	0.21	0.20	0.24
Efficiency & Turnover
Asset Turnover TTM	0.09	0.18	0.26	0.30	0.27	0.19	0.15	0.12	0.11	0.09	0.12	1.09
Days Sales Outstanding TTM	42.08	65.73	104.12	72.00	51.56	108.55	180.08	266.94	235.46	353.92	126.95	28.80
Receivables Turnover TTM	8.67	5.55	3.51	5.07	7.08	3.36	2.03	1.37	1.55	1.03	2.88	12.67
Per Share Metrics
Diluted EPS TTM	-2.05	-1.37	-1.08	-0.84	-0.95	-1.51	-1.62	-1.49	-1.47	-1.65	-1.72	0.96
Free Cash Flow Per Share TTM	-1.07	-1.03	-0.46	-0.82	-0.49	-1.03	-1.48	-0.74	-1.22	-0.98	-1.75	2.73
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-418.99%	-140.35%	-87.34%	-52.51%	-67.32%	-133.77%	-179.69%	-222.37%	-219.04%	-294.42%	-181.62%	14.13%
Net Profit Margin TTM	-404.00%	-126.33%	-76.56%	-47.16%	-59.96%	-121.73%	-160.80%	-182.75%	-179.42%	-249.63%	-156.13%	14.50%
Growth Metrics
Net Revenue Growth (1Y)	-69.78%	-12.98%	38.87%	116.21%	95.94%	85.05%	0.38%	-86.74%	-86.22%	-	-	-
Net Income Growth (1Y)	103.59%	-9.70%	-33.88%	-44.20%	-34.52%	-9.76%	3.39%	-267.18%	-330.38%	-	-	-
EPS Growth (1Y)	110.12%	-9.09%	-33.49%	-43.94%	-33.60%	-8.51%	-6.13%	-254.98%	-302.90%	-	-	-
Valuation Metrics
P/E TTM	-12.72	-18.21	-24.47	-20.40	-12.83	-7.88	-9.05	-8.41	-5.78	-6.36	-6.03	6.58
P/B TTM	23.74	11.43	7.39	4.04	2.83	2.76	3.28	2.60	1.60	1.83	1.54	1.05
P/S TTM	51.39	23.01	18.74	9.62	7.70	9.59	14.55	15.36	10.37	15.89	9.41	0.95
Market Cap	1.91B	1.87B	1.99B	1.29B	945.48M	895.29M	1.11B	955.41M	650.10M	801.78M	715.49M	447.45M
Enterprise Value	1.73B	1.63B	1.94B	1.23B	847.23M	819.08M	1.04B	833.06M	579.14M	686.97M	557.93M	353.12M
Calculated Values
Free Cash Flow TTM	-78.47M	-77.04M	-34.53M	-62.09M	-37.04M	-77.61M	-112.05M	-56.63M	-93.45M	-75.06M	-120.78M	192.64M
Net Debt	-179.41M	-244.28M	-41.16M	-64.83M	-98.25M	-76.20M	-66.10M	-122.36M	-70.96M	-114.81M	-157.56M	-94.33M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-12Sale

Owner: Hollywood, Mark

Title: EVP & Chief Operating Officer

Shares: 6,120

Price/Share: $22.67

Value: $138,740.40

Shares Owned: 132,913

Relationship: Officer

Ownership: Direct

2026-01-12Sale

Owner: Moore, Paul Andrew

Title: Chief Scientific Officer

Shares: 9,560

Price/Share: $22.67

Value: $216,725.20

Shares Owned: 48,497

Relationship: Officer

Ownership: Direct

2026-01-12Sale

Owner: Smith, Jeffrey T L

Title: EVP & Chief Medical Officer

Shares: 9,310

Price/Share: $22.67

Value: $211,057.70

Shares Owned: 26,708

Relationship: Officer

Ownership: Direct

2026-01-12Sale

Owner: Galbraith, Kenneth

Title: Chair & CEO

Shares: 30,424

Price/Share: $22.67

Value: $689,712.08

Shares Owned: 226,842

Relationship: Director,Officer

Ownership: Direct

2026-01-05Sale

Owner: Moore, Paul Andrew

Title: Chief Scientific Officer

Shares: 20,110

Price/Share: $25.10

Value: $504,761.00

Shares Owned: 31,212

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-12	Hollywood, Mark	Officer	EVP & Chief Operating Officer	Direct	Sale	6,120	22.67	$138,740.40	132,913	4
2026-01-12	Moore, Paul Andrew	Officer	Chief Scientific Officer	Direct	Sale	9,560	22.67	$216,725.20	48,497	4
2026-01-12	Smith, Jeffrey T L	Officer	EVP & Chief Medical Officer	Direct	Sale	9,310	22.67	$211,057.70	26,708	4
2026-01-12	Galbraith, Kenneth	Director,Officer	Chair & CEO	Direct	Sale	30,424	22.67	$689,712.08	226,842	4
2026-01-05	Moore, Paul Andrew	Officer	Chief Scientific Officer	Direct	Sale	20,110	25.10	$504,761.00	31,212	4
2026-01-05	Galbraith, Kenneth	Director,Officer	Chair & CEO	Direct	Sale	54,343	25.10	$1,364,009.30	158,286	4
2026-01-05	Smith, Jeffrey T L	Officer	EVP & Chief Medical Officer	Direct	Sale	10,538	25.10	$264,503.80	18,352	4
2025-12-22	Galbraith, Kenneth	Director,Officer	Chair & CEO	Direct	Sale	47,528	27.02	$1,284,206.56	133,275	4
2025-05-19	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	5,919	11.78	$69,725.82	17,883,908	4
2025-04-17	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	54,760	11.52	$630,835.20	17,828,487	4
2025-04-04	Nodelman, Oleg, Ecor1 Cap…	Director,TenPercentOwner	-	Indirect	Purchase	196,438	11.17	$2,194,212.46	17,699,774	4
2025-04-02	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	74,360	11.85	$881,166.00	17,382,566	4
2025-03-26	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	43,848	12.24	$536,699.52	17,255,151	4
2025-03-24	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	22,689	13.08	$296,772.12	17,157,802	4
2025-03-19	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	58,306	12.64	$736,987.84	17,030,604	4
2025-03-13	Nodelman, Oleg, Ecor1 Cap…	Director,TenPercentOwner	-	Indirect	Purchase	468,356	12.48	$5,845,082.88	16,802,141	4
2025-01-17	Ecor1, Capital, Llc	Director,TenPercentOwner	-	Indirect	Purchase	19,748	13.87	$273,904.76	15,720,161	4
2025-01-15	Ecor1, Capital, Llc	Director,TenPercentOwner	-	Indirect	Purchase	39,029	14.01	$546,796.29	15,578,732	4
2025-01-10	Ecor1, Capital, Llc	Director,TenPercentOwner	-	Indirect	Purchase	204,098	13.13	$2,679,806.74	15,411,078	4
2025-01-06	Smith, Jeffrey T L	Officer	EVP & Chief Medical Officer	Direct	Sale	11,110	14.92	$165,761.20	8,890	4
2025-01-06	Galbraith, Kenneth	Director,Officer	Chair & CEO	Direct	Sale	57,291	14.92	$854,781.72	47,543	4
2025-01-06	Moore, Paul Andrew	Officer	Chief Scientific Officer	Direct	Sale	21,200	14.92	$316,304.00	14,741	4
2025-01-02	Ecor1, Capital, Llc	Director,TenPercentOwner	-	Indirect	Purchase	157,880	14.78	$2,333,466.40	15,185,959	4
2024-12-27	Ecor1, Capital, Llc	Director,TenPercentOwner	-	Indirect	Purchase	101,659	14.49	$1,473,038.91	14,822,590	4
2024-12-23	Ecor1, Capital, Llc	Director,TenPercentOwner	-	Indirect	Purchase	251,502	14.25	$3,583,903.50	14,692,281	4/A
2024-01-08	Astle, Christopher	Officer	SVP & Chief Financial Officer	Direct	Sale	1,431	11.22	$16,055.82	6,503	4
2024-01-08	Galbraith, Kenneth	Director,Officer	Chair & CEO	Direct	Sale	5,706	11.22	$64,021.32	23,762	4
2024-01-08	Moore, Paul Andrew	Officer	Chief Scientific Officer	Direct	Sale	2,339	11.22	$26,243.58	7,367	4
2023-12-11	Astle, Christopher	Officer	SVP & Chief Financial Officer	Direct	Sale	886	9.13	$8,089.18	1,997	4
2023-06-16	Ecor1, Capital, Llc	TenPercentOwner	-	Indirect	Purchase	3,350,000	8.12	$27,202,000.00	13,437,473	4
2023-03-28	Ecor1, Capital, Llc	TenPercentOwner	-	Indirect	Purchase	200,000	8.00	$1,600,000.00	10,087,473	4
2023-03-10	Klompas, Neil A	Officer	President & COO	Direct	Sale	2,977	7.83	$23,309.91	17,032	4
2023-01-20	Ecor1, Capital, Llc	TenPercentOwner	-	Indirect	Purchase	163,400	9.88	$1,614,392.00	9,887,473	4
2023-01-18	Ecor1, Capital, Llc	TenPercentOwner	-	Indirect	Purchase	203,000	10.00	$2,030,000.00	9,579,973	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

93.34%

Inst. Shares: 69,694,986

Shares Outstanding: 74,668,790

2025-12-31

91.33%

Inst. Shares: 68,869,050

Shares Outstanding: 75,404,897

2025-09-30

96.40%

Inst. Shares: 73,043,363

Shares Outstanding: 75,767,778

2025-06-30

96.60%

Inst. Shares: 72,775,172

Shares Outstanding: 75,337,168

2025-03-31

89.60%

Inst. Shares: 67,356,514

Shares Outstanding: 75,171,020

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	69,694,986	74,668,790	93.34%
2025-12-31	68,869,050	75,404,897	91.33%
2025-09-30	73,043,363	75,767,778	96.40%
2025-06-30	72,775,172	75,337,168	96.60%
2025-03-31	67,356,514	75,171,020	89.60%
2024-12-31	63,309,779	75,846,681	83.47%
2024-09-30	63,262,131	76,128,531	83.10%
2024-06-30	65,152,951	76,392,593	85.29%
2024-03-31	62,943,911	76,214,833	82.59%
2023-12-31	60,625,121	68,863,010	88.04%
2023-09-30	58,611,964	70,575,773	83.05%
2023-06-30	59,832,623	67,281,028	88.93%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Zymeworks Inc. (ZYME) — SEC Financial Statements & Analysis

Zymeworks Inc. (ZYME) is a pharmaceutical preparations company, incorporated in DE. Zymeworks Inc. trades on Nasdaq as: ZYME. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Zymeworks Inc. reported a -69.78% year-over-year revenue growth, a Debt-to-Equity ratio of 3.94x, a Price-to-Sales (P/S) ratio of 51.39x (TTM), a Price-to-Book (P/B) ratio of 23.74x (TTM), at a market cap of $1.91B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -69.78%
Debt To Equity: 3.94x
P/S TTM: 51.39x
P/B TTM: 23.74x
Market Cap: $1.91B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Zymeworks Inc. in?

Zymeworks Inc. (ZYME) operates in the Pharmaceutical Preparations industry.

What is ZYME's market cap?

Zymeworks Inc. (ZYME) has a market capitalization of $1.91B as of 2026-06-30.

What exchange does ZYME trade on?

Zymeworks Inc. (ZYME) trades on the Nasdaq.

Where is Zymeworks Inc. incorporated?

Zymeworks Inc. is incorporated in DE.

Zymeworks Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Zymeworks Inc. (ZYME) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Zymeworks Inc. (ZYME) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.